The immune checkpoint inhibitors, the most thoroughly investigated class of immunotherapy, target programmed death 1 (PD-1) receptor, its ligand (PD-L1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), being its objective stimulate the immune response of patients against cancer cells (2). The gene discussed is CTLA4; the disease is cancer.